Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

E. Krop, Ian; A. Jegede, Opeyemi; E. Grilley-Olson, Juneko; D. Lauring, Josh; P. Mitchell, Edith; A. Zwiebel, James; J. Gray, Robert; Wang, Victoria; M. McShane, Lisa; V. Rubinstein, Larry; Patton, David; Mickey Williams, P.; R. Hamilton, Stanley; A. Kono, Scott; M. Ford, James; A. Garcia, Agustin; D. Sui, Xingwei; D. Siegel, Robert; M. Slomovitz, Brian; A. Conley, Barbara; L. Arteaga, Carlos; N. Harris, Lyndsay; J. O'Dwyer, Peter; P. Chen, Alice; T. Flaherty, Keith

doi:10.1200/po.21.00424

Public

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

Published in JCO Precision Oncology • Feb 9, 2022

Authors:

Ian E. Krop

Opeyemi A. Jegede

Juneko E. Grilley-Olson

Abstract

PURPOSE PIK3CA mutations frequently contribute to oncogenesis in solid tumors. Taselisib, a potent and selective inhibitor of phosphoinositide 3-kinase, has demonstrated clinical activity in PIK3CA-mutant breast cancer. Whether PIK3CA mutations predict sensitivity to taselisib in other cancer types ...

Subject

Medicine

Lung cancer

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!